CJC-1295 and Ipamorelin are the most commonly prescribed peptides in the anti-aging and functional medicine space. They are the backbone of growth hormone optimization programs, prescribed at thousands of longevity clinics, hormone therapy practices, and wellness centers nationwide.
If you operate in the anti-aging, functional medicine, men’s health, women’s health, or performance optimization space, this is the program your patients are already researching. This guide covers how CJC-1295 and Ipamorelin work, who the right patients are, how to structure a program, and what the economics look like for a practice or clinic operator.
How CJC-1295 and Ipamorelin Work Together
Growth hormone (GH) naturally declines with age, dropping approximately 15 percent per decade after age 30. By age 45, most adults have roughly 60 percent of the GH output they had at 25. This decline contributes to muscle loss, fat accumulation, slower recovery, reduced sleep quality, and accelerated aging at the cellular level.
CJC-1295 and Ipamorelin address this decline through two complementary mechanisms:
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH). It binds to GHRH receptors in the pituitary gland, stimulating synthesis and release of growth hormone. The version commonly used in compounding (CJC-1295 with DAC, or Drug Affinity Complex) has an extended half-life of 6 to 8 days, creating sustained GH elevation rather than a single acute pulse.
Ipamorelin is a growth hormone secretagogue (GHS) and selective ghrelin receptor agonist. It triggers GH release through a different receptor pathway than CJC-1295, producing a sharp GH pulse that mimics natural pulsatile release without significantly increasing cortisol or prolactin.
The synergy: When used together, CJC-1295 amplifies the baseline GH signal and extends GH availability while Ipamorelin produces a clean, acute peak. The combination consistently produces higher GH output than either peptide alone with a more physiologic release pattern.
The result is increased GH and downstream IGF-1 without the supraphysiologic levels and receptor downregulation associated with exogenous HGH injections.
What Patients Experience
The clinical effects of CJC-1295/Ipamorelin accumulate over weeks to months. Understanding the timeline helps set appropriate patient expectations:
Weeks 1-4: Sleep improvement. The pituitary releases the majority of daily GH during deep sleep. Patients frequently report deeper, more restorative sleep within the first few weeks. This is often the first effect patients notice and frequently the one that drives early retention.
Weeks 4-8: Recovery and energy. Faster recovery from training, reduced muscle soreness, increased energy. Patients who exercise regularly notice this clearly. Sedentary patients may notice increased general vitality.
Weeks 8-16: Body composition changes. Increased lean muscle mass and reduced body fat become measurable. These changes require adequate protein intake and exercise to manifest fully. Patients who combine the program with appropriate nutrition and training see the strongest body composition effects.
Months 3-6: Deeper anti-aging effects. Skin quality, connective tissue strength, joint health, cognitive function. These changes are more subtle but represent the cellular-level benefits that long-term patients value most and that drive continued subscription.
Ongoing: Long-term optimization. Many patients stay on CJC-1295/Ipamorelin indefinitely as part of a broader longevity and wellness protocol, cycling on and off based on individual response and goals.
Who to Target: Patient Profile
The strongest candidates for a CJC-1295/Ipamorelin program:
Age 35 to 65 with symptomatic GH decline. Presenting symptoms: difficulty maintaining muscle, increasing body fat (especially visceral), poor sleep quality, slower workout recovery, fatigue, reduced libido. These are your bread-and-butter patients.
Existing hormone optimization patients. If you already run TRT or hormone replacement programs, CJC-1295/Ipamorelin is a natural add-on. These patients are already engaged in proactive health management and are comfortable with injection protocols.
Athletes and high performers aged 30 and older. Competitive athletes, weekend warriors, executives, and biohackers who prioritize performance and recovery. This group self-selects; they come in already educated and motivated.
Anti-aging and longevity patients. Patients who are investing in comprehensive longevity protocols. Often have lab work showing low IGF-1 relative to age-matched norms.
Post-injury or post-surgical recovery. BPC-157 is the primary recovery peptide, but CJC-1295/Ipamorelin contributes to systemic tissue repair and anabolism that supports recovery. Some practitioners stack both.
Screening Questions for Intake
- Age and primary goal (body composition, sleep, recovery, anti-aging)
- Current medications (especially diabetes medications, as GH affects insulin sensitivity)
- Active cancer diagnosis or history (exclude; GH stimulation is contraindicated)
- Diabetes or significant insulin resistance (requires careful monitoring)
- Acromegaly or gigantism history (exclude)
- Previous peptide or HGH use
Labs to consider: IGF-1 baseline, fasting glucose, HbA1c. IGF-1 is the primary biomarker for monitoring GH axis activity and response to treatment.
Protocol Structure
Standard Injection Protocol
| Parameter | CJC-1295 w/ DAC | Ipamorelin |
|---|---|---|
| Dose | 1-2 mg | 200-300 mcg |
| Route | Subcutaneous | Subcutaneous |
| Frequency | 1-2x per week | Nightly (bedtime) |
| Combination | Mixed or separate | Same syringe typically |
| Duration | 3-6 month minimum | Ongoing |
The most common clinical approach is a combined injection of CJC-1295/Ipamorelin given nightly at bedtime to align with the natural circadian GH pulse. Some protocols use CJC-1295 less frequently (1-2x/week) given its longer half-life.
Monitoring
- IGF-1 at baseline and 6 to 8 weeks into treatment
- Fasting glucose if there are metabolic concerns
- Symptom check-in at 4 weeks (primarily sleep quality, energy)
- Full protocol review at 12 weeks
Cycling
Some practitioners cycle CJC-1295/Ipamorelin (5 days on, 2 days off, or similar patterns) to maintain pituitary sensitivity. Others prescribe continuous daily dosing. The clinical evidence on cycling is not definitive; practice varies based on prescriber preference and patient response.
Building the Program: Pricing and Structure
Pricing Models
| Program Tier | Monthly Price | What’s Included |
|---|---|---|
| Starter | $249/mo | CJC-1295 / Ipamorelin injection, provider oversight |
| Standard | $299/mo | Starter + IGF-1 lab at 8 weeks |
| Premium | $399/mo | Standard + quarterly lab panel + unlimited messaging |
Bundling Opportunities
CJC-1295/Ipamorelin bundles naturally with:
- BPC-157 for patients with active injuries or post-surgical recovery needs
- Testosterone replacement for men with confirmed low testosterone
- GHK-Cu for patients focused on skin and connective tissue quality
- PT-141 for patients with sexual wellness goals
Multi-program patients have significantly higher lifetime value and tend to be your most loyal subscribers. The growth hormone optimization program is often the anchor program that keeps patients engaged while they add other programs over time.
Minimum Commitment
Given the 8 to 12 week timeline to see full results, a 3-month minimum commitment is standard practice and reasonable to require. Frame this to patients as a scientific commitment: “We want to give the program enough time to show what it can do. Most patients see the full picture at 12 weeks.” Quarterly billing or a discounted 3-month prepay option reduces churn from impatient early dropouts.
Regulatory and Compliance Considerations
FDA Status
CJC-1295 and Ipamorelin are on the FDA’s bulk drug substance list under review for 503A compounding eligibility. The PCAC review scheduled for July 2026 will determine whether these peptides receive Category 1 status (confirmed compounding eligibility) or face restrictions.
As of 2026, many 503A compounding pharmacies continue to compound CJC-1295/Ipamorelin for individual patients with valid prescriptions. Verify current status with your pharmacy partner before launching.
Not a Controlled Substance
CJC-1295 and Ipamorelin are not scheduled substances and do not require a DEA number to prescribe. Standard prescriber NPI and state licensure apply.
Not a Substitute for TRT
Be precise in your marketing. CJC-1295/Ipamorelin stimulates natural GH production through the pituitary. It does not replace testosterone, and its effects are distinct from hormone replacement therapy. Avoid marketing language that conflates GH optimization with TRT or hormone replacement.
Off-Label Use and Informed Consent
All CJC-1295/Ipamorelin use is off-label, as neither compound has FDA approval for any indication. Patients should receive informed consent documentation that clearly states the off-label nature, the available evidence base (primarily animal and observational), and the experimental nature of the treatment.
The Market Opportunity
The global growth hormone secretagogue market is growing rapidly, driven by increasing demand for anti-aging interventions, performance optimization, and longevity medicine. CJC-1295/Ipamorelin is positioned at the intersection of several of the fastest-growing health categories:
- Longevity medicine is attracting significant consumer and investor attention
- Men’s health optimization (beyond testosterone) is expanding rapidly
- Performance and recovery is a mainstream conversation among adults over 35
- Sleep optimization is one of the most searched health topics globally
Your target patients are not fringe biohackers. They are mainstream adults who are paying attention to how they age and are willing to invest in evidence-adjacent interventions when offered through a trusted medical source.
Economics: A Growth Hormone Program at Scale
Unit Economics (Full Clinic Model)
| Revenue | $299/mo (avg) |
|---|---|
| Platform fee (prorated) | -$14 |
| Pharmacy cost per fill | -$55-$75 |
| Provider cost | -$0-$25 |
| Gross profit per patient | $185-$230/mo |
Retention-Adjusted Revenue
Growth hormone optimization programs have among the highest retention rates in peptide therapy because results accumulate over time and patients are invested in the process. Typical retention: 10 to 14 months.
| Active Patients | Monthly Revenue | Annual Revenue | Annual Gross Profit |
|---|---|---|---|
| 30 | $8,970 | $107,640 | $66,000-$82,800 |
| 75 | $22,425 | $269,100 | $166,000-$207,000 |
| 150 | $44,850 | $538,200 | $333,000-$415,000 |
At 150 patients with average 12-month retention, gross profit exceeds $333,000 annually from a single peptide program.
How to Start
A turnkey peptide telehealth platform provides the prescriber network, pharmacy integrations, patient portal, and billing infrastructure to launch a CJC-1295/Ipamorelin program without building custom technology.
Timeline: 1 to 2 weeks from account setup to first patient enrollment.
What you bring: Your audience, your marketing, your brand, and your understanding of who needs this program.
What the platform brings: Licensed providers in all 50 states, direct pharmacy integrations, HIPAA-compliant infrastructure, patient management tools, and subscription billing.
The CJC-1295/Ipamorelin program is among the highest-retention, highest-value programs you can offer. The patient demand is there. The clinical rationale is there. The infrastructure is available.
Explore partnership options with Karpa Health to launch your growth hormone peptide program.
Want to understand the full peptide program landscape before choosing? Read the complete turnkey peptide telehealth guide or explore peptide prescribing requirements.
Book a call with Karpa Health if you want help structuring the right program.